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The PIKfyve Inhibitor YM201636 Blocks the Continuous
Recycling of the Tight Junction Proteins Claudin-1 and
Claudin-2 in MDCK cells
Joseph D. Dukes, Paul Whitley*., Andrew D. Chalmers*.
Department of Biology and Biochemistry, Centre for Regenerative Medicine, University of Bath, Bath, United Kingdom
Abstract
Tight junctions mediate the intercellular diffusion barrier found in epithelial tissues but they are not static complexes;
instead there is rapid movement of individual proteins within the junctions. In addition some tight junction proteins are
continuously being endocytosed and recycled back to the plasma membrane. Understanding the dynamic behaviour of
tight junctions is important as they are altered in a range of pathological conditions including cancer and inflammatory
bowel disease. In this study we investigate the effect of treating epithelial cells with a small molecule inhibitor (YM201636)
of the lipid kinase PIKfyve, a protein which is involved in endocytic trafficking. We show that MDCK cells treated with
YM201636 accumulate the tight junction protein claudin-1 intracellularly. In contrast YM201636 did not alter the localization
of other junction proteins including ZO-1, occludin and E-cadherin. A biochemical trafficking assay was used to show that
YM201636 inhibited the endocytic recycling of claudin-1, providing an explanation for the intracellular accumulation.
Claudin-2 was also found to constantly recycle in confluent MDCK cells and treatment with YM201636 blocked this recycling
and caused accumulation of intracellular claudin-2. However, claudin-4 showed negligible endocytosis and no detectable
intracellular accumulation occurred following treatment with YM201636, suggesting that not all claudins show the same
rate of endocytic trafficking. Finally, we show that, consistent with the defects in claudin trafficking, incubation with
YM201636 delayed formation of the epithelial permeability barrier. Therefore, YM201636 treatment blocks the continuous
recycling of claudin-1/claudin-2 and delays epithelial barrier formation.
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Introduction
Cell-cell contacts between epithelial cells are mediated via
different types of specialised junctional complexes, including tight
junctions, adherens junctions and desmosomes [1,2,3]. The most
apical of these complexes, the tight junctions, are composed of
transmembrane proteins including claudin family proteins,
occludin like proteins, junctional adhesion molecules (JAMs) and
plaque proteins such as ZO-1 [4]. Tight junctions control the
paracellular flux of molecules across epithelial sheets and
selectivity is determined by claudin composition [5].
Despite providing an efficient barrier to permeability it appears
that tight junctions are not static structures [4]. Junctional
components can be rapidly altered by an array of environmental,
physiological and cell cycle-dependent stimuli [6,7]. These include
TNFawhich drives the internalization of tight junction proteins such
as occludin [8], thus altering barrier function. In addition to stimulus
induced endocytosis, there is mounting evidence that tight junctions
show dynamic behaviour in unstimulated epithelial monolayers [4].
There is movement of individual tight junction proteins within the
tight junctions [9] and claudin-1 is constantly endocytosed and
recycled back to the plasma membrane in a range of epithelial cell
lines [10]. Occludin also constantly recycles in some epithelial cell
lines, but not in MDCK cells [10,11]. Understanding how these
dynamic events are involved in the formation, maintenance and
modulation of tight junctions is important as changes in tight
junctions have been linked to a wide range of pathological conditions
including inflammatory bowel diseases and cancer [6,7,12,13,14].
Our recent data shows that the constitutive recycling of claudin-1 is
dependent upon the Endosomal Sorting Complex Required for
Transport (ESCRT) [10]. The ESCRTmachinery, which is made up
of ESCRT 0, I, II and III sub-complexes, is required for multiple
endocytic trafficking events [15]. ESCRTs have a well established role
in the trafficking of transmembrane proteins to the lysosome, but are
also required for a number of other processes including, autophagy
[16] and endosome to TGN trafficking [17], although this block does
not appear to be complete [18]. The ESCRT-III component Vps24/
CHMP3, has been shown to bind the phosphoinositide PtdIns(3,5)P2
[19] which is produced from the early endosomally localised lipid
PtdIns(3)P by the lipid kinase PIKfyve [20,21]. The enzyme PIKfyve
and its lipid product, like the ESCRT machinery, have been
implicated in the endosome to lysosome pathway [22], autophagy
[23] and endosome to TGN trafficking [24]. PIKfyve has also been
linked to tumour invasion [25], insulin stimulated translocation of the
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glucose transporter GLUT4 [26], replication of salmonella [27] and
regulation of glutamate transporters [28].
Here we address whether addition of a small molecule inhibitor
(YM201636) of PIKfyve [29] to epithelial MDCK cells perturbs tight
junctions. Our data shows that YM201636 inhibits the constant
recycling of claudin-1 and causes it to accumulate intracellularly. In
contrast the localisation of ZO-1, occludin and E-cadherin appeared
unchanged. We then examined if other claudins behaved like
claudin-1. Claudin-2 was found to be constantly endocytosed and
recycled in a similar way to claudin-1. Treatment with YM201636
inhibited claudin-2 recycling and caused it to accumulate intracel-
lularly. In contrast clauin-4 showed a much lower rate of endocytosis
and YM201636 treatment did not appreciably change the
localisation of this protein, arguing that different claudin proteins
show different flux through the endocytic system. Finally, we show
that, consistent with the defects in claudin trafficking, addition of
YM201636 delayed formation of an epithelial permeability barrier.
In summary, addition of YM201636 blocked the continuous
recycling of claudin-1 and claudin-2 and delayed barrier formation
in epithelial cells. To the best of our knowledge this is the first small
molecule inhibitor that has been shown to block the recycling of
these tight junction proteins.
Results
Claudin-1 accumulates intracellularly after treating MDCK
cells with YM201636
MDCK cells were treated with the small molecule inhibitor of
PIKfyve (YM201636) [29] and stained for a range of junctional
proteins (Figure 1). A dramatic accumulation of claudin-1 on
Figure 1. Addition of the PIKfyve inhibitor YM201636 results in intracellular accumulation of claudin-1. YM201636 treated MDCK cells
showed no difference in localisation of ZO-1, occludin, E-cadherin or PKCi/f when compared with vehicle treated control cells (A–B left panels and C–
E). In contrast, the localisation of claudin-1 was dramatically affected by YM201636 treatment, resulting in extensive internal accumulation of the
protein (B, middle panel) compared with vehicle control (A, middle panel). Arrows highlight internal claudin-1. Arrowheads highlight claudin-1 that
remained at the junctions. Scale bars 10 mm.
doi:10.1371/journal.pone.0028659.g001
YM201636 and Claudin-1 Recycling
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internal structures of cells treated with YM201636 was observed
(Figure 1B, arrows). The accumulation of internal caludin-1
coincided with a reduction in plasma membrane staining, however
some claudin-1 appeared to remain at the plasma membrane
(Figure 1B, arrowheads) so not all claudin-1 relocalised intracellu-
larly. In contrast, localization of the junctional proteins ZO-1,
occludin and E-cadherin appeared unaffected by the addition of
YM201636 (Figure 1 B, C, D). The localization of the polarity
protein aPKCf/i also appeared normal after YM201636 treatment
(Figure 1E). The accumulation of internal claudin-1 was rapid and
increased intracellular claudin-1 could be seen after a 30 minute
treatment with YM201636 and extensive accumulation was seen
after two hours in a time course experiment (Figure S1).
YM201636 treatment blocked the constant recycling of
claudin-1
We then investigated what trafficking event is being inhibited by
YM201636. In order to test the possibility that the accumulation
was due to a failure in trafficking of newly synthesised claudin-1 to
the plasma membrane, cells were treated with YM201636 in the
presence of cyclohexamide to inhibit protein synthesis. Claudin-1
accumulation was still observed (Figure S1B), suggesting that it was
not newly synthesised protein but endocytosed claudin-1 that was
accumulating.
Claudin-1 is known to be constantly endocytosed and recycled
in MDCK cells [10]. In contrast no degradation occurs over the
time course of these experiments, so the build up of intracellular
protein could not be caused by a block in degradation. To
determine whether inhibition of PIKfyve altered the normal
endocytosis and recycling of cell surface claudin-1 the biotinylation
assay described previously [10,11] was used. In control cells 35%
of the surface labelled claudin-1 was internalised after 60 min
(Figure 2, ‘‘Endocytosis 60 min’’). Proteins that are recycled back
to the plasma membrane become accessible to stripping reagent so
recycling is shown by a reduction in signal in the ‘‘Recycling
20 min’’ lane compared to the ‘‘Endocytosis 60 min’’ lane
(Figure 2). In control cells the majority of the internalised
claudin-1 underwent recycling back to the surface after an
additional 20 minute incubation at 37uC. The amount of
endocytosis and recycling of claudin-1 is consistent with our
previous work [10]. In contrast, in cells treated with YM201636 all
of the surface biotinylated claudin-1 was internalised after
60 minutes (Figure 2, ‘‘Endocytosis + YM201636’’). In addition,
when cells were treated with YM201636 none of the internalised
claudin-1 was returned to the plasma membrane following the
second incubation (Figure 2, ‘‘Recycling + YM201636’’). This
result indicates that YM201636 treatment blocked the constitutive
recycling of claudin-1, causing an intracellular accumulation of the
endocytosed protein.
Claudin-2 is constantly recycled in MDCK cells and this
recycling is blocked by YM201636
The claudin family contains more than 20 members [30], so to
see if the trafficking of other members was affected by treatment
with YM201636 MDCK cells were stained with antibodies for
claudin-2. This showed striking accumulation of intracellular
claudin-2 following treatment with YM201636 (Figure 3A, arrows)
although some remained at the junctions (Figure 3A, arrowheads).
The claudin-2 protein which did accumulate intracellularly
colocalised with claudin-1.
The immunofluorescence suggests that claudin-2 might be
undergoing similar recycling to claudin-1. However, previous work
has only examined the trafficking of claudin-1 [10] so the
biotinylation assay was used to look at the endocytosis,
degradation and recycling of claudin-2 (Figure 3B+C). Endocytosis
is shown by a signal in the ‘Endocytosis 60 min’ lane, degradation
by a reduction in the ‘Degradation Control’ compared to the
‘Endocytosis 60 min’ lane and recycling by a reduction in
‘Recycling 20 min’ compared to the ‘Degradation Control’.
Claudin-2 was found to be endocytosed and recycled without
detectable degradation in the time frame of these experiments
(Figure 3B+C). This trafficking profile is very similar to claudin-1.
Addition of YM201636 blocked this recycling and caused an
accumulation of endocytosed claudin-2 (Figure 3B+C).
Claudin-4 does not show intracellular accumulation
following YM201636 treatment and has a low rate of
endocytosis
Claudin-1 and claudin-2 show a similar response to treatment
with YM201636 and have similar profiles of endocytosis and
recycling. However, it cannot be assumed that this will apply to all
claudins. In fact there was no change in the localisation of claudin-
4 following a two hour treatment with YM201636 (Figure 4A).
One explanation for the lack of claudin-4 accumulation is that it
is trafficked along a pathway which is not blocked by treatment
with YM201636. Alternatively, it might be that the rate of claudin-
4 endocytosis is much lower than that seen for claudin-1 and
claudin-2. This occurs with occludin, which does not show
significant endocytosis after a one hour incubation in MDCK cells
[10]. The biotinylation assay was used to measure the endocytosis
of claudin-4 and following a one hour incubation negligible
internal claudin-4 was present (Figure 4 B+C). Therefore, the rate
of claudin-4 endocytosis appears to be much less than for claudin-
1 and claudin-2. This demonstrates that there is variation in the
rate that claudins are trafficked through the endocytic system and
provides a possible explanation for the lack of accumulation seen
after addition of YM201636.
Treatment with YM201636 delays formation of a
functional tight junction permeability barrier
Finally, we investigated whether YM201636 treatment had an
effect on the tight junction permeability barrier. Our initial
experiments on confluent cells showed no difference between the
transepithelial resistance (TER) of YM201636 treated cells and
vehicle control treated cells (not shown). We then investigated the
establishment of tight junctions using a calcium switch assay [31].
Cells depleted of calcium showed a loss of claudin-1, ZO-1 and
occludin staining at the junctions (Figure 5, left panels). In control
cells these proteins returned to cell junctions following repletion of
calcium (Figure 5, middle panels). When cells were repleted with
calcium in the presence of YM201636, occludin returned to cell
junctions at a comparable rate to that observed in control cells
(Figure 5C, right panel). However, both claudin-1 and ZO-1 failed
to return to the junctions in YM201636 treated cells (Figure 5A+B,
right panels). A failure of tight junction proteins to efficiently
return to the plasma membrane might alter barrier function. To
assess this we measured TER following calcium switch and found
that cells treated with YM201636 showed a slower rate of recovery
of TER in comparison to control cells (Figure 5D). This shows that
YM201636 treatment delays the return of tight junction proteins
to the plasma membrane and impairs formation of a correct
epithelial permeability barrier.
Discussion
The constant recycling of claudin-1 proteins represents a newly
described and poorly understood feature of epithelial cells. In this
YM201636 and Claudin-1 Recycling
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study we show that claudin-2 is also recycled and that addition of
the PIKfyve inhibitor YM201636 interferes with normal claudin-1
and claudin-2 recycling causing accumulation of intracellular
claudin proteins. In contrast, in the time frame of these assays
claudin-4 underwent negligible endocytosis and the localisation of
claudin-4 was not altered by YM201636 treatment. Finally,
YM201636 treatment delayed formation of an epithelial perme-
ability barrier, consistent with the alterations in claudin trafficking.
Small molecule inhibitors provide a tractable tool for looking at
effects of acutely inhibiting kinase activity and the most likely
explanation for our results is that YM201636 is acting by
inhibiting PIKfyve. However, the PIKfyve inhibitor may affect
Figure 2. YM201636 blocks the recycling of claudin-1. A surface biotinylation assay was performed on control or YM201636 treated MDCK
cells. (A) The ‘Surface Biotinylated’ lane represents the initial biotinylated claudin-1 at the cell surface. Labelled claudin-1 that is internal after 60 min
and is resistant to surface stripping is represented for control (‘Endocytosis 60 min’) and YM201636 treated (‘Endocytosis + YM201636) cells. Claudin-1
remaining internal (and thus not recycled back to the surface) following recycling for 20 min is represented as ‘Recycling 20 min’ for control and
‘Recycling + YM201636’ for treated cells. The recycled cargo is then determined as the reduction in signal in the recycling lanes compared to the
endocytosis lanes. Addition of YM201636 blocked claudin-1 recycling and caused accumulation of endocytosed protein. Our previous study shows
that degradation of claudin-1 does not occur over this timeframe [10] so a block in degradation does not account for the accumulation of internal
claudin-1. (B) Results represented graphically show the mean from 3 independent experiments, error bars are SEM.
doi:10.1371/journal.pone.0028659.g002
YM201636 and Claudin-1 Recycling
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Figure 3. Claudin-2 is constantly recycled in MDCK cells and this recycling is inhibited by YM201636. (A) MDCK cells treated with
YM201636, but not DMSO controls, showed accumulation of internal claudin-2 which colocalised with the internal claudin-1 (arrows). Some claudin-2
remained at the junctions (arrowheads). Scale bars 10 mm. (B) A surface biotinylation assay was performed on control or YM201636 treated MDCK
cells and a Western blot from a representative experiment is shown. (C) Results represented graphically show the mean from four independent
experiments, error bars are SEM. Claudin-2 was found to be endocytosed (endocytosis 60 min) and recycled (shown by the reduction in the ‘Recycling
20 min’ lane compared to the ‘Degradation Control’ lane). Degradation would be shown by a reduction in the ‘Degradation Control’ compared to the
‘Endocytosis 60 min’ but the mean from four experiments showed there was no detectable degradation over this time scale (shown graphically in C).
Addition of YM201636 inhibited claudin-2 recycling and caused accumulation of endocytosed proteins.
doi:10.1371/journal.pone.0028659.g003
YM201636 and Claudin-1 Recycling
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multiple targets [32] and to rule out non-specific effects a second
structurally distinct inhibitor is required [33]. To our knowledge
no such inhibitor is currently available for PIKfyve, so here we
conclude that treatment with YM201636 produces the phenotypes
described and future work is needed to confirm that YM201636 is
functioning via inhibition of PIKfyve.
What is particularly striking about this study was the differences
seen between different junction proteins. A very prominent re-
localisation of claudin-1 and claudin-2 was seen in the presence of
YM201636. In contrast the localisation of other junctional
proteins appeared to be indistinguishable from mock-treated cells
even after 2 hr of incubation. A similar result was also seen after
inhibition of ESCRT function [10]. These results emphasise the
different trafficking itineraries that junctional proteins may
undertake in epithelial cells. E-cadherin undergoes constitutive
internalisation into the endocytic pathway, and has been suggested
to traffic through Rab11 positive apical recycling vesicles in
MDCK cells [34]. However in this and our previous study on
ESCRT proteins [10] we saw no effect on E-cadherin localisation
suggesting that E-cadherin and claudins follow distinct recycling
pathways. Different tight junction membrane proteins are known
to be internalised independently of one another [35,36].
Figure 4. Claudin-4 does not accumulate following YM201636 treatment and undergoes negligible endocytosis. (A) MDCK cells
treated with YM201636 showed no detectable accumulation of internal claudin-4. Scale bars 10 mm. (B) A surface biotinylation assay was performed
to measure the endocytosis of claudin-4 and a Western blot from a representative experiment is shown. (C) Results represented graphically show the
mean from three independent experiments, error bars are SEM. Claudin-4 was successfully biotinylated (Surface Biotinylated) but negligible claudin-4
was internalised (Endocytosis 60 min) suggesting that claudin-4 is endocytosed at a much lower rate than claudin-1 and claudin-2.
doi:10.1371/journal.pone.0028659.g004
YM201636 and Claudin-1 Recycling
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Furthermore claudin-1 and occludin internalise into different
compartments in MDCK cells following calcium depletion [37]
and return to the plasma membrane with different kinetics upon
calcium repletion [38]. We propose that claudin-1 and claudin-2
follow a distinct trafficking route in epithelial cells that is sensitive
to addition of YM201636 and inhibition of ESCRT activity. This
pathway is not well defined but may involve Rab13 [38], a
GTPase implicated in TGN-endosome or an endosome-TGN
retrieval pathway [39]. Interestingly claudin-4 underwent negligi-
ble endocytosis in the time frame analysed, suggesting that
individual claudins have different rates of flux through the
endocytic system.
Figure 5. YM201636 impairs tight junction formation following a calcium switch. (A–C) Cells were stained for junctional proteins following
calcium removal and showed a loss of staining at the junctions (left panels). Calcium was reintroduced in either control (middle panels) or YM201636
containing media (right panels) and cells were stained for junctional proteins. All proteins showed recovery to the junctions in control conditions.
However, following YM201636 treatment claudin-1 and to a lesser extent ZO-1 failed to fully return to the junctions. (D) The transepithelial resistance
(TER) of MDCK cells following calcium switch was determined. Treatment with YM201636 caused a delayed recovery of TER. Graphs represent the
averages from 3 independent experiments (plus 3 replicates per experiment) and error bars show SEM.
doi:10.1371/journal.pone.0028659.g005
YM201636 and Claudin-1 Recycling
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Previous work used live imaging to look at the dynamics of
individual tight junction components over 10–20 minute intervals
[9]. This showed that 75% of claudin-1 is stable within the
junction while 25% is mobile. Our experiments look at a different
aspect of the dynamics of individual tight junction proteins and
demonstrate that after an hour approximately 35% of biotinylated
claudin-1 is endocytosed ([10]and this work). In addition treatment
with YM201636 causes almost 100% of biotinylated claudin-1 to
accumulate internally due to the block in recycling. Therefore, the
biotin assay suggests that more claudin-1 is mobile than the live
imaging methods. A possible explanation for the discrepancy is
that the biotinylation is preferentially labelling the claudin-1 which
is mobile within the junction, perhaps because it is more accessible
than the immobile fraction. This would be consistent with our
immunofluorescence data which shows that, despite the large
amount of claudin-1 which accumulates internally, some remains
at the junctions. If this model is correct then the fraction of
junctional claudin which is mobile within the junctions is also
rapidly endocytosed and recycled through the endocytic system.
Addition of YM201636 did not alter the TER of confluent
monolayers despite causing a striking relocalisation of claudin-1
and claudin-2 to an intracellular pool. This may be due to the fact
that some claudin-1 and claudin-2 remained at the junctions.
Alternatively it might be because claudin-1 is thought to promote a
‘tight’ seal while claudin-2 is believed to be pore forming [30,40].
The reduction of one may compensate for the loss of the other. In
contrast to the situation in confluent monolayers, following a
calcium switch YM201636 treatment reduced the rate of barrier
formation. This suggests that formation of an epithelial seal is
more sensitive to perturbation with YM201636 than the
maintenance of mature junctions. Treatment with YM201636
reduced the amount of claudin-1 which returned to the junctions
following a calcium switch, unlike occludin which returned
normally. There was also a delay in the return of ZO-1 back to
the cell junctions. This was unexpected as there was no effect on
ZO-1’s localisation in confluent epithelia treated with YM201636.
ZO-1 acts as a scaffolding protein that anchors both claudins and
occludin to the actin cytoskeleton [41]. We observed some
claudin-1 remaining at the junctions after YM201636 treatment
and this immobile junctional claudin-1 could anchor ZO-1 at the
membrane. In the case of the calcium switch experiments we fail
to see any significant claudin-1 returning to the junctions upon
calcium repletion, which might explain why ZO-1 is not recruited.
This model assumes that the occludin which returns normally after
a calcium switch is not sufficient to recruit ZO-1. Future work will
need to look at the effects that inhibiting the trafficking of
individual junction proteins has on the establishment and
maintenance of tight junctions.
In summary, YM201636 treatment causes a block in the
endocytic recycling of claudin-1 and claudin-2 and a delay in
formation of an epithelial seal. To the best of our knowledge this is
the first small molecule inhibitor that has been shown to block the
recycling of these tight junction proteins.
Materials and Methods
Antibodies and reagents
Rabbit anti-claudin-1 (59–9000), mouse anti-claudin-2 (32–
5600), mouse anti-claudin-4 (32–9400), rabbit anti-occludin (71–
1500), mouse anti-occludin (33–1500), mouse ZO-1 (33–9100) and
mouse E-cadherin (33–4000) were all purchased from Zymed (San
Fransico, CA, U.S.A.). Rabbit anti-PKCf (C-20; sc-216) was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
U.S.A.). Species-specific fluorophore (Alexa FluorH 546 and 488)-
conjugated anti-IgG secondary antibodies were all purchased from
Invitrogen. Goat anti-mouse-HRP conjugated secondary antibody
was obtained from Sigma and goat anti-rabbit-HRP was
purchased from Pierce (Rockford, IL, U.S.A.). All other reagents
were purchased from Sigma, unless stated otherwise.
Cell culture and YM201636 treatment
MDCK type II cells [42] (ECACC, cat no: 00062107) were
maintained at 37uC and 5% CO2 in DMEM (Dulbecco’s modified
Eagle’s medium) supplemented with 10% (v/v) FBS (fetal bovine
serum), 2 mM L-glutamine, 100 units/ml penicillin and 100 mg/
ml streptomycin (all from Lonza). Cells were plated onto 13 mm
coverslips in 24-well plates (Nunc) and grown 3 d post-confluence
prior to treatments. In the case of treatments with YM201636 (and
controls), cells were serum starved (complete growth medium
lacking FBS) overnight. YM201636 dissolved in DMSO (a kind
gift from Professor Peter Shepherd, University of Auckland, New
Zealand) was diluted with DMEM and added to cells at a final
concentration of 800 nM. Cells were treated with YM201636 or a
DMSO control for 2 h unless stated. For TER measurements cells
were plated at confluency on Transwell (Corning, Corning, NY,
U.S.A., cat no. 3470) permeable polyester filters (0.4 mm pore size)
with surface area of 0.33 cm2. Media was changed ever 2–3 days
and cells were grown for 7 days prior to TER measurements.
Immunofluorescence
At 24 h post-transfection, cells were fixed with Methanol cooled
to -20uC for 10 min. In the case of double staining with anti-
claudin-1 and anti-claudin-2, cells were fixed with 4% PFA for
20 min, and then permeabilised with 0.1% TritonX-100 for
15 min. These and other subsequent steps were all performed at
room temperature. Cells were then blocked with 10% (v/v) FBS
for 30 min. Primary and secondary antibodies were diluted in 2%
FBS-PBS (2% FBS in PBS) and cells were incubated with primary
antibodies for ,2 h and ,1 h for secondary antibodies. Cells
were washed five times for 5 min with 2% FBS-PBS following all
antibody incubations. Stained cells were then mounted in Mowiol
(Calbiochem, San Diego, CA, U.S.A.) and examined on a Zeiss
LSM510 laser-scanning confocal microscope and appropriate
images taken.
Endocytosis and recycling biotin assays
The biotinylation assay to study endocytosis and recycling of
tight junction proteins was described previously [10,11]. Briefly,
MDCK II cells plated on to 35 mm dishes grown for at least 3 d
past confluence and then serum starved over night. Cells were
transferred to ice and washed with phosphate buffered saline
supplemented with calcium and magnesium (PBS-CM). Cells were
then incubated with the cleavable non-membrane permeable
sulfo-NHS-SS-biotin (Pierce, cat no: 21331; in PBS-CM) at a
concentration of 0.5 mg/ml and incubated with cells for 30 min
on ice. Free biotin was then quenched using 50 mM NH4Cl (in
PBS-CM) for 15 min (4uC). For the endocytosis assay, pre-warmed
serum-free medium with either 800 nM YM201636 or DMSO (as
a control) was added and cells returned to 37uC for indicated
times. Cells were then transferred to ice to stop endocytosis, and
surface (non-endocytosed) biotin was stripped by reduction with
100 mM 2-mercaptoethanesulfonate (in tris-buffered saline sup-
plemented with calcium and magnesium; TBS-CM) for 30 min
(4uC). Internalised biotinylated cargo was protected from biotin
stripping with MESNA by an intact membrane. Free –SH groups
were then quenched by incubating cells with 5 mg/ml iodoace-
tamide (in PBS-CM) for 15 min. For the recycling assay this
process was repeated with 20 min incubations at 37uC in serum-
YM201636 and Claudin-1 Recycling
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free medium supplemented with either YM201636 or DMSO. To
control for any loss of biotinylated cargo by degradation, cells were
subjected to the full recycling assay in parallel with the recycling
condition however the final stripping step was omitted. Thus any
loss of biotinylated cargo from this condition would indicate
degradation in the 20 min post-endocytosis. To control for the
efficiency of surface stripping by MESNA, surface labelled cells
were incubated with MESNA as described immediately after
surface labelling. Cells were lysed (1.25% (v/v) Triton X-100,
0.25% (w/v) SDS, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
5 mM EDTA, 5 mg/ml iodoacetamide, 10 ug/ml APMSF) on
ice, pulse sonicated, and spun to remove large/nuclear debris. An
equal volume of the post-nuclear supernatant was taken from each
sample for use as a loading control. Biotinylated proteins were
collected by incubation with Neutravidin beads (Pierce, cat no:
29200,), rotating overnight at 4uC. Beads were then washed by
spinning at 1000 g, 5 times with wash buffer (0.5% (v/v) Triton X-
100, 0.1% (w/v) SDS, 50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
5 mM EDTA) and 3 times with PBS-CM. Reducing sample buffer
was then added to each sample to cleave biotinylated proteins
from the beads, and following boiling samples were loaded onto a
15% tris-glycine SDS-PAGE gel. Separated proteins were
transferred to nitrocellulose and immunoblotted for the presence
of claudin-1 and occludin. Signals were detected by ECLH
(enhanced chemiluminescence) or Chemiglow West Chemilumi-
nescence Substrate (Alpha Innotech, San Leandro, CA, USA) and
quantified using an Optichem detector with associated software
(Ultra Violet Products). For quantification of the biotinylated
proteins, the amount of claudin-1 and occludin was normalized to
their respective total protein bands determined from non-isolated
lysate samples run. Where results were plotted graphically, values
were expressed as a percentage of the total claudin-1 biotinylated
at the surface only.
Calcium switch and trans-epithelial resistance (TER)
Media was removed from cells on cover slips or filters (basal and
apical chambers), washed once with Dulbecco’s phosphate
buffered saline (low calcium) and replaced with no calcium
essential minimal Eagle’s medium. Following 60 min incubation
with essential minimal Eagle’s medium (37uC) the media was
removed and replaced with normal complete growth medium
(times indicated) for calcium repletion. For TER studies
YM201636 or DMSO was added to both apical and basal
chambers, where appropriate. Measurements of TER were carried
out using the EVOM TER machine with an EndohmTM chamber
(World Precision Instruments, Sarasota, FL, U.S.A.). Measure-
ments of resistance were taken at 60 min intervals and the
percentage change in TER (compared to starting TER measure-
ment) was plotted graphically for analysis.
Supporting Information
Figure S1 Intracellular claudin-1 accumulates rapidly
and is not blocked by addition of cyclohexamide. (A)
YM201636 treatment results in rapid claudin-1 accumulation in
MDCK cells. MDCK cells were treated with YM201636 for
indicated times (0 min is no treatment), fixed and stained for
claudin-1. Increased internal staining of claudin-1 over control
(0 min) is observed after 30 min and continues to accumulate over
a period of 6 hours. (B) Claudin-1 accumulation is seen in the
presence of cyclohexamide. MDCK cells were treated with
cyclohexamide (CHX) to inhibit synthesis of new protein and
then treated with either DMSO as a vehicle control (left panel) or
YM201636 (right panel) for 2 h. Cells were fixed and stained for
claudin-1. Scale bars represent 10 mm.
(TIF)
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